India’s ban on antimicrobial fixed-dose combinations: winning the battle, losing the war?

BACKGROUND AND OBJECTIVES: India, the country with the largest market availability of antimicrobial fixed-dose combinations (FDCs), banned certain antimicrobial FDCs in September 2018. Our objective was to examine the impact of Government ban on the sales of antimicrobial FDCs. METHODS: The sales pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Sulis, Giorgia, Pradhan, Richeek, Kotwani, Anita, Gandra, Sumanth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047325/
https://www.ncbi.nlm.nih.gov/pubmed/35484606
http://dx.doi.org/10.1186/s40545-022-00428-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047325/
https://www.ncbi.nlm.nih.gov/pubmed/35484606
http://dx.doi.org/10.1186/s40545-022-00428-w

Ejemplares similares